Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmar...
Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share (AMRN)
Last amarin corporation plc - american depositary shares, each representing one ordinary share earnings: 4/30 05:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.amarincorp.com/investors
Company Research
Source: GlobeNewswire
Cardiovascular disease events like heart attacks, stroke and death affect millions of patients in the United States and are estimated to cost $500 billion annuallyMillions of high-risk patients with cardiovascular disease could benefit from this cost-effective therapy if expanded label receives FDA approval; PDUFA date is December 28 DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) has voted unanimously (16-0) to recommend approval of an indication and label expansion for Vascepa® (icosapent ethyl) capsules to reduce the risk of cardiovascular events in high-risk patients based on results from the landmark REDUCE-IT®1 cardiovascular outcomes trial. The FDA is not bound by the recommendations of an advisory committee. Amarin plans to work with the agency as it completes its review of the c
Show less
Read more
Impact Snapshot
Event Time:
AMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMRN alerts
High impacting Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share news events
Weekly update
A roundup of the hottest topics
AMRN
News
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Amarin Announces Two Upcoming Investor EventsGlobeNewswire
- Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal OfficerBusiness Wire
- Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial OfficerPR Newswire
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual EuropeGlobeNewswire
AMRN
Earnings
- 10/30/24 - Beat
AMRN
Sec Filings
- 10/31/24 - Form 3
- 10/30/24 - Form 10-Q
- 10/30/24 - Form 8-K
- AMRN's page on the SEC website